New drug combo targets tough blood cancers
NCT ID NCT04493138
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining two drugs, azacitidine and quizartinib, can help people with myelodysplastic syndromes or related blood cancers that have specific genetic changes (FLT3 or CBL mutations). The trial involves 30 adults and aims to find the best dose and see how well the combination works at controlling the disease. It is still in early stages, so the main focus is on safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- azacitidine and quizartinib
- What this could lead to
- If successful, this combination could offer a new treatment option for people with certain genetic mutations in myelodysplastic syndromes and related blood cancers.
- What could go wrong
- This is an early-phase trial with only 30 participants, so results may not apply broadly. Side effects from the drug combination are possible and are being closely monitored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can trained immune cells stop blood cancer relapse?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can donor immune cells tame stem cell transplant risks?
- Can a Two-Drug combo tame a rare blood cancer?